vs
Apellis Pharmaceuticals, Inc.（APLS）与Hagerty, Inc.（HGTY）财务数据对比。点击上方公司名可切换其他公司
Hagerty, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$388.1M vs $199.9M），Hagerty, Inc.净利率更高（7.4% vs -29.5%，领先36.8%），Hagerty, Inc.同比增速更快（16.5% vs -5.9%），Hagerty, Inc.自由现金流更多（$194.5M vs $-14.3M），过去两年Hagerty, Inc.的营收复合增速更高（19.5% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
哈格蒂（Hagerty, Inc.）是美国知名汽车生活方式及会员服务企业，同时是全球规模最大的经典老爷车特种保险供应商，总部位于密歇根州特拉弗斯城，业务范围覆盖加拿大、德国及英国市场。
APLS vs HGTY — 直观对比
营收规模更大
HGTY
是对方的1.9倍
$199.9M
营收增速更快
HGTY
高出22.4%
-5.9%
净利率更高
HGTY
高出36.8%
-29.5%
自由现金流更多
HGTY
多$208.7M
$-14.3M
两年增速更快
HGTY
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $388.1M |
| 净利润 | $-59.0M | $28.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 10.2% |
| 净利率 | -29.5% | 7.4% |
| 营收同比 | -5.9% | 16.5% |
| 净利润同比 | -62.2% | 238.4% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSHGTY
| Q4 25 | $199.9M | $388.1M | ||
| Q3 25 | $458.6M | $380.0M | ||
| Q2 25 | $178.5M | $368.7M | ||
| Q1 25 | $166.8M | $319.6M | ||
| Q4 24 | $212.5M | $333.2M | ||
| Q3 24 | $196.8M | $323.4M | ||
| Q2 24 | $199.7M | $313.2M | ||
| Q1 24 | $172.3M | $271.7M |
净利润APLSHGTY
| Q4 25 | $-59.0M | $28.6M | ||
| Q3 25 | $215.7M | $46.2M | ||
| Q2 25 | $-42.2M | $47.2M | ||
| Q1 25 | $-92.2M | $27.3M | ||
| Q4 24 | $-36.4M | $8.4M | ||
| Q3 24 | $-57.4M | $19.0M | ||
| Q2 24 | $-37.7M | $42.7M | ||
| Q1 24 | $-66.4M | $8.2M |
营业利润率APLSHGTY
| Q4 25 | -25.6% | 10.2% | ||
| Q3 25 | 48.7% | 9.0% | ||
| Q2 25 | -18.6% | 12.9% | ||
| Q1 25 | -50.0% | 8.1% | ||
| Q4 24 | -12.3% | 1.8% | ||
| Q3 24 | -24.0% | 3.1% | ||
| Q2 24 | -14.7% | 12.2% | ||
| Q1 24 | -36.0% | 4.5% |
净利率APLSHGTY
| Q4 25 | -29.5% | 7.4% | ||
| Q3 25 | 47.0% | 12.2% | ||
| Q2 25 | -23.6% | 12.8% | ||
| Q1 25 | -55.3% | 8.5% | ||
| Q4 24 | -17.1% | 2.5% | ||
| Q3 24 | -29.2% | 5.9% | ||
| Q2 24 | -18.9% | 13.6% | ||
| Q1 24 | -38.5% | 3.0% |
每股收益（稀释后）APLSHGTY
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $160.2M |
| 总债务越低越好 | — | $177.9M |
| 股东权益账面价值 | $370.1M | $221.3M |
| 总资产 | $1.1B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 0.80× |
8季度趋势，按日历期对齐
现金及短期投资APLSHGTY
| Q4 25 | $466.2M | $160.2M | ||
| Q3 25 | $479.2M | $290.5M | ||
| Q2 25 | $370.0M | $259.6M | ||
| Q1 25 | $358.4M | $232.7M | ||
| Q4 24 | $411.3M | $178.7M | ||
| Q3 24 | $396.9M | $208.9M | ||
| Q2 24 | $360.1M | $186.4M | ||
| Q1 24 | $325.9M | $131.2M |
总债务APLSHGTY
| Q4 25 | — | $177.9M | ||
| Q3 25 | — | $104.4M | ||
| Q2 25 | — | $153.4M | ||
| Q1 25 | — | $132.6M | ||
| Q4 24 | — | $105.8M | ||
| Q3 24 | — | $122.9M | ||
| Q2 24 | — | $98.0M | ||
| Q1 24 | $93.1M | $91.5M |
股东权益APLSHGTY
| Q4 25 | $370.1M | $221.3M | ||
| Q3 25 | $401.2M | $211.7M | ||
| Q2 25 | $156.3M | $172.3M | ||
| Q1 25 | $164.2M | $162.9M | ||
| Q4 24 | $228.5M | $150.3M | ||
| Q3 24 | $237.1M | $148.3M | ||
| Q2 24 | $264.3M | $94.4M | ||
| Q1 24 | $266.7M | $93.5M |
总资产APLSHGTY
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $821.4M | $2.0B | ||
| Q1 25 | $807.3M | $1.8B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.8B | ||
| Q2 24 | $904.5M | $1.7B | ||
| Q1 24 | $831.9M | $1.6B |
负债/权益比APLSHGTY
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.49× | ||
| Q2 25 | — | 0.89× | ||
| Q1 25 | — | 0.81× | ||
| Q4 24 | — | 0.70× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | 1.04× | ||
| Q1 24 | 0.35× | 0.98× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $194.5M |
| 自由现金流率自由现金流/营收 | -7.1% | 50.1% |
| 资本支出强度资本支出/营收 | 0.1% | 6.3% |
| 现金转化率经营现金流/净利润 | — | 7.67× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $365.8M |
8季度趋势，按日历期对齐
经营现金流APLSHGTY
| Q4 25 | $-14.2M | $219.0M | ||
| Q3 25 | $108.5M | $92.2M | ||
| Q2 25 | $4.4M | $53.9M | ||
| Q1 25 | $-53.4M | $43.8M | ||
| Q4 24 | $19.4M | $177.0M | ||
| Q3 24 | $34.1M | $67.4M | ||
| Q2 24 | $-8.3M | $64.0M | ||
| Q1 24 | $-133.0M | $58.2M |
自由现金流APLSHGTY
| Q4 25 | $-14.3M | $194.5M | ||
| Q3 25 | $108.3M | $85.2M | ||
| Q2 25 | $4.4M | $47.7M | ||
| Q1 25 | $-53.4M | $38.4M | ||
| Q4 24 | $19.3M | $155.7M | ||
| Q3 24 | — | $62.0M | ||
| Q2 24 | $-8.4M | $56.6M | ||
| Q1 24 | $-133.3M | $53.7M |
自由现金流率APLSHGTY
| Q4 25 | -7.1% | 50.1% | ||
| Q3 25 | 23.6% | 22.4% | ||
| Q2 25 | 2.5% | 12.9% | ||
| Q1 25 | -32.0% | 12.0% | ||
| Q4 24 | 9.1% | 46.7% | ||
| Q3 24 | — | 19.2% | ||
| Q2 24 | -4.2% | 18.1% | ||
| Q1 24 | -77.3% | 19.8% |
资本支出强度APLSHGTY
| Q4 25 | 0.1% | 6.3% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 6.4% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 2.4% | ||
| Q1 24 | 0.2% | 1.7% |
现金转化率APLSHGTY
| Q4 25 | — | 7.67× | ||
| Q3 25 | 0.50× | 2.00× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.61× | ||
| Q4 24 | — | 20.97× | ||
| Q3 24 | — | 3.55× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 7.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HGTY
暂无分部数据
